NCT05009329Active, not recruitingPhase 1/2
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
Multi-center, Open, Dose-escalation, and Expanded Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JAB-21822 in Advanced Solid Tumors With KRAS p.G12C Mutation
Source: ClinicalTrials.gov · Last updated 13 Aug 2026
Brief summary (registry, in English)
To assess safety, tolerability, PK, efficacy and determine recommended phase 2 dose (RP2D) of JAB-21822 (glecirasib) administered in adult participants with KRAS p.G12C-mutant advanced solid tumors.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 315 (actual)
- First submitted
- 26 Jul 2021
- Start date
- 26 Jul 2021
- Primary completion date
- Aug 2026
- Lead sponsor
- Allist Pharmaceuticals, Inc.
- Diseases
- Lung cancer
- NCT number
- NCT05009329
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 315
- From 26 Jul 2021 to the primary completion date, Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously treated with KRAS G12C inhibitor
- Previous allogeneic bone marrow transplant or organ transplant
- Intended study subjects who were unable to abstain from alcohol during medication
Other illness
- History of intestinal disease or major gastric surgery or inability to swallow oral medications
- Other active cancer
- Active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV)
- Impaired heart function or clinically significant heart disease
- Other unqualified conditions judged by the investigators
Other
- Pregnant or breast-feeding
Who the study is looking for
- Written informed consent
- Advanced (metastatic or unresectable) KRAS p.G12C mutant solid tumors, with failure or absence of standard treatment
- Subject must be ≥18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
- Subjects with life expectancy ≥3 months.
- Subjects must have at least one measurable lesion as defined by RECIST v1.1.
- There was no serious organ dysfunction in the screening stage
- Male or female subjects of reproductive age agree to use adequate contraception
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Cancer Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
Related publications
- The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation.Hum Cell · 2026 · PMID 42384131
- Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials.Lancet Gastroenterol Hepatol · 2026 · PMID 41344351
This page is information, not medical advice. Discuss any trial with your doctor.